Skip to content
Dose Brief
Menu

Methodology

The Brief Score, explained

Dose Brief is a newsroom, so we score providers the way we'd report them: on what actually happens to your price and your supply. Every GLP-1 provider here is scored out of 100 on the same six weighted factors — the identical rubric for every provider. Assume any provider we list may compensate us; either way, a score is our editorial judgment, built from each provider's public disclosures and our tracking, and it is never sold. A score and a slot are two different things, though, and this page would mislead if it only told you about the first: on the score-ranked boards, desks we have a commercial relationship with are listed first, and within each group the score decides. The number beside a name is the real one either way, which is exactly what makes the ordering checkable. The standards that judgment is held to are set out in our editorial policy, who runs the desk and how it is funded is on the about page, and the same scored field is cut into rankings by question on our guide to the price rankings.

The six factors

1. Price Stability

22%

The heaviest factor. Does the headline monthly price hold, or is it a teaser first-month rate that silently resets to full price? A flat, no-step-up line you can plan around scores highest; bait-and-switch tiers score lowest, no matter how low the intro number.

2. Supply Reliability

20%

Whether the provider can actually keep filling your prescription — sourcing stability, pharmacy relationships, and exposure to the compounded-supply headlines and FDA shortage-list swings that strand patients mid-titration.

3. Transparency

18%

How much the provider puts on the record: an explicit price, a named states-served list, clinician and supply-chain disclosure. Opaque 'contact us for pricing' models lose points here.

4. Access Breadth

15%

How many states served, both molecules or one, and whether there are oral/sublingual and brand-name routes — the wider the honest access, the higher the score.

5. Clinical Oversight

13%

Whether a licensed clinician — not just a web form — stands behind the prescription, with real titration guidance and side-effect support after the first vial ships.

6. Track Record

12%

How long the provider has operated, how it has handled past pricing and supply changes, and whether its reputation holds up under scrutiny.

How we stay honest

This page is editorial information, not medical advice. Compounded GLP-1 medications are not FDA-approved finished drug products. Talk to a licensed clinician before starting any weight-management medication. See our affiliate disclosure and medical disclaimer.

← Back to the ranking